AQR Capital Management
RLMD icon

AQR Capital Management’s Relmada Therapeutics RLMD Stock Holding History

AQR Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-36,991
Closed -$83.6K – 2265
2023
Q1 		$83.6K Buy
36,991
+6,648
+22% +$22.9K ﹤0.01% 2127
2022
Q4 		$106K Buy
+30,343
New +$266K ﹤0.01% 2137
2020
Q4 		– Sell
-7,656
Closed -$288K – 2253
2020
Q3 		$288K Buy
+7,656
New +$296K ﹤0.01% 1929

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

AQR Capital Management's RLMD Position: Q2 2023 in Review

AQR Capital Management sold out of Relmada Therapeutics (RLMD) in Q2 2023, closing a stake of 36,991 shares — an estimated $83.6K sold.

AQR Capital Management first reported a position in RLMD in Q3 2020 and held it in 3 quarters. The position peaked at $288K in Q3 2020. 95 funds tracked by Wall St. Rank hold RLMD as of Q2 2023.

  • AQR Capital Management reported no remaining Relmada Therapeutics position as of Q2 2023 after selling out during the quarter.
  • AQR Capital Management sold 36,991 Relmada Therapeutics shares in Q2 2023, an estimated $83.6K.
  • AQR Capital Management first reported a position in Relmada Therapeutics in Q3 2020 and held it in 3 quarters.
  • AQR Capital Management's Relmada Therapeutics position peaked at $288K in Q3 2020.
  • 95 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2023.

Based on AQR Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.